Combination Drug Therapy for the Management of Chronic Neuropathic Pain
Chronic neuropathic pain (NP) is an increasingly prevalent disease and leading cause of disability which is challenging to treat. Several distinct classes of drugs are currently used for the treatment of chronic NP, but each drug targets only narrow components of the underlying pathophysiological me...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/13/12/1802 |
| _version_ | 1797381813283323904 |
|---|---|
| author | Serena Boccella Lidia De Filippis Cristina Giorgio Laura Brandolini Meghan Jones Rubina Novelli Ezio Amorizzo Matteo Luigi Giuseppe Leoni Gaetano Terranova Sabatino Maione Livio Luongo Manuela Leone Marcello Allegretti Enrico Maria Minnella Andrea Aramini |
| author_facet | Serena Boccella Lidia De Filippis Cristina Giorgio Laura Brandolini Meghan Jones Rubina Novelli Ezio Amorizzo Matteo Luigi Giuseppe Leoni Gaetano Terranova Sabatino Maione Livio Luongo Manuela Leone Marcello Allegretti Enrico Maria Minnella Andrea Aramini |
| author_sort | Serena Boccella |
| collection | DOAJ |
| description | Chronic neuropathic pain (NP) is an increasingly prevalent disease and leading cause of disability which is challenging to treat. Several distinct classes of drugs are currently used for the treatment of chronic NP, but each drug targets only narrow components of the underlying pathophysiological mechanisms, bears limited efficacy, and comes with dose-limiting side effects. Multimodal therapies have been increasingly proposed as potential therapeutic approaches to target the multiple mechanisms underlying nociceptive transmission and modulation. However, while preclinical studies with combination therapies showed promise to improve efficacy over monotherapy, clinical trial data on their efficacy in specific populations are lacking and increased risk for adverse effects should be carefully considered. Drug-drug co-crystallization has emerged as an innovative pharmacological approach which can combine two or more different active pharmaceutical ingredients in a single crystal, optimizing pharmacokinetic and physicochemical characteristics of the native molecules, thus potentially capitalizing on the synergistic efficacy between classes of drugs while simplifying adherence and minimizing the risk of side effects by reducing the doses. In this work, we review the current pharmacological options for the treatment of chronic NP, focusing on combination therapies and their ongoing developing programs and highlighting the potential of co-crystals as novel approaches to chronic NP management. |
| first_indexed | 2024-03-08T20:57:51Z |
| format | Article |
| id | doaj.art-8bbf5bb8bb154cb0b526fbf73da40a77 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-08T20:57:51Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-8bbf5bb8bb154cb0b526fbf73da40a772023-12-22T13:56:10ZengMDPI AGBiomolecules2218-273X2023-12-011312180210.3390/biom13121802Combination Drug Therapy for the Management of Chronic Neuropathic PainSerena Boccella0Lidia De Filippis1Cristina Giorgio2Laura Brandolini3Meghan Jones4Rubina Novelli5Ezio Amorizzo6Matteo Luigi Giuseppe Leoni7Gaetano Terranova8Sabatino Maione9Livio Luongo10Manuela Leone11Marcello Allegretti12Enrico Maria Minnella13Andrea Aramini14Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via De Amicis, 80131 Naples, ItalyResearch & Early Development (R&D), Dompé Farmaceutici S.p.A, Via S. Lucia, 20122 Milan, ItalyResearch & Early Development (R&D), Dompé Farmaceutici S.p.A, Via De Amicis, 80131 Naples, ItalyResearch & Early Development (R&D), Dompé Farmaceutici S.p.A, Via Campo di Pile, 67100 L’Aquila, ItalyResearch & Early Development (R&D), Dompé US, 181 2nd Avenue, STE 600, San Mateo, CA 94401, USAResearch & Early Development (R&D), Dompé Farmaceutici S.p.A, Via S. Lucia, 20122 Milan, ItalyPain Unit, San Paolo Hospital, 00053 Civitavecchia, ItalyAzienda USL di Piacenza, 29121 Piacenza, ItalyPain Unit, ASST Gaetano Pini, 20122 Milan, ItalyDepartment of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyResearch & Early Development (R&D), Dompé Farmaceutici S.p.A, Via S. Lucia, 20122 Milan, ItalyResearch & Early Development (R&D), Dompé Farmaceutici S.p.A, Via Campo di Pile, 67100 L’Aquila, ItalyResearch & Early Development (R&D), Dompé Farmaceutici S.p.A, Via S. Lucia, 20122 Milan, ItalyResearch & Early Development (R&D), Dompé Farmaceutici S.p.A, Via Campo di Pile, 67100 L’Aquila, ItalyChronic neuropathic pain (NP) is an increasingly prevalent disease and leading cause of disability which is challenging to treat. Several distinct classes of drugs are currently used for the treatment of chronic NP, but each drug targets only narrow components of the underlying pathophysiological mechanisms, bears limited efficacy, and comes with dose-limiting side effects. Multimodal therapies have been increasingly proposed as potential therapeutic approaches to target the multiple mechanisms underlying nociceptive transmission and modulation. However, while preclinical studies with combination therapies showed promise to improve efficacy over monotherapy, clinical trial data on their efficacy in specific populations are lacking and increased risk for adverse effects should be carefully considered. Drug-drug co-crystallization has emerged as an innovative pharmacological approach which can combine two or more different active pharmaceutical ingredients in a single crystal, optimizing pharmacokinetic and physicochemical characteristics of the native molecules, thus potentially capitalizing on the synergistic efficacy between classes of drugs while simplifying adherence and minimizing the risk of side effects by reducing the doses. In this work, we review the current pharmacological options for the treatment of chronic NP, focusing on combination therapies and their ongoing developing programs and highlighting the potential of co-crystals as novel approaches to chronic NP management.https://www.mdpi.com/2218-273X/13/12/1802chronic paincombination pharmacotherapyco-crystalanalgesia |
| spellingShingle | Serena Boccella Lidia De Filippis Cristina Giorgio Laura Brandolini Meghan Jones Rubina Novelli Ezio Amorizzo Matteo Luigi Giuseppe Leoni Gaetano Terranova Sabatino Maione Livio Luongo Manuela Leone Marcello Allegretti Enrico Maria Minnella Andrea Aramini Combination Drug Therapy for the Management of Chronic Neuropathic Pain Biomolecules chronic pain combination pharmacotherapy co-crystal analgesia |
| title | Combination Drug Therapy for the Management of Chronic Neuropathic Pain |
| title_full | Combination Drug Therapy for the Management of Chronic Neuropathic Pain |
| title_fullStr | Combination Drug Therapy for the Management of Chronic Neuropathic Pain |
| title_full_unstemmed | Combination Drug Therapy for the Management of Chronic Neuropathic Pain |
| title_short | Combination Drug Therapy for the Management of Chronic Neuropathic Pain |
| title_sort | combination drug therapy for the management of chronic neuropathic pain |
| topic | chronic pain combination pharmacotherapy co-crystal analgesia |
| url | https://www.mdpi.com/2218-273X/13/12/1802 |
| work_keys_str_mv | AT serenaboccella combinationdrugtherapyforthemanagementofchronicneuropathicpain AT lidiadefilippis combinationdrugtherapyforthemanagementofchronicneuropathicpain AT cristinagiorgio combinationdrugtherapyforthemanagementofchronicneuropathicpain AT laurabrandolini combinationdrugtherapyforthemanagementofchronicneuropathicpain AT meghanjones combinationdrugtherapyforthemanagementofchronicneuropathicpain AT rubinanovelli combinationdrugtherapyforthemanagementofchronicneuropathicpain AT ezioamorizzo combinationdrugtherapyforthemanagementofchronicneuropathicpain AT matteoluigigiuseppeleoni combinationdrugtherapyforthemanagementofchronicneuropathicpain AT gaetanoterranova combinationdrugtherapyforthemanagementofchronicneuropathicpain AT sabatinomaione combinationdrugtherapyforthemanagementofchronicneuropathicpain AT livioluongo combinationdrugtherapyforthemanagementofchronicneuropathicpain AT manuelaleone combinationdrugtherapyforthemanagementofchronicneuropathicpain AT marcelloallegretti combinationdrugtherapyforthemanagementofchronicneuropathicpain AT enricomariaminnella combinationdrugtherapyforthemanagementofchronicneuropathicpain AT andreaaramini combinationdrugtherapyforthemanagementofchronicneuropathicpain |